Source comparison
Melanotan-2 for Erectile Function: Dosing Comparison
Understanding how different Melanotan-2 doses compare in efficacy and tolerability is essential for designing research protocols. 0.5mg 40–50% 2–4 hours 4–6 hours 10–15% (mild nausea, flushing) Minimal efficacy, well-tolerated—useful for initial dose-finding s
This comparison does not assign a generated winner or score.
- Understanding how different Melanotan-2 doses compare in efficacy and tolerability is essential for designing research protocols.
- 0.5mg
- 40–50%
- 2–4 hours
- 4–6 hours
- 10–15% (mild nausea, flushing)
- Minimal efficacy, well-tolerated—useful for initial dose-finding studies
- 1.0mg
- 70–80%
- 1–3 hours
- 6–12 hours
- 35–40% (nausea, flushing, yawning)
- Optimal balance of efficacy and tolerability for most research applications
- 1.5mg
- 80–85%
- 1–2 hours
- 8–14 hours
- 50–60% (moderate nausea, facial flushing, stretching)
- Higher response but increased adverse events—reserve for refractory populations
- 2.0mg
- 85–90%
- 10–16 hours
- 65–75% (significant nausea, vomiting in 10–15%)
- Marginal efficacy gain with substantial tolerability cost—rarely justified
- The 1.0mg dose represents the sweet spot for Melanotan-2 for erectile function research: high response rates, manageable adverse event profile, and sufficient duration to assess meaningful endpoints. Doses above 1.5mg increase adverse events without proportional efficacy gains.